candesartan and moexiprilat

candesartan has been researched along with moexiprilat in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Grohé, C; Löbbert, K; Stimpel, M; van Eickels, M; Vetter, H	1
Grohé, C; van Eickels, M; Vetter, H	1

Other Studies

2 other study(ies) available for candesartan and moexiprilat

Article	Year
Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. Naunyn-Schmiedeberg's archives of pharmacology, 1999, Volume: 359, Issue:5 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Benzimidazoles; Biphenyl Compounds; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Fibroblasts; Flavonoids; Heart; Immunoblotting; Isoquinolines; Phosphorylation; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Signal Transduction; STAT3 Transcription Factor; Tetrahydroisoquinolines; Tetrazoles; Time Factors; Trans-Activators	1999
Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation. British journal of pharmacology, 2000, Volume: 131, Issue:8 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Benzimidazoles; Biphenyl Compounds; Bromodeoxyuridine; Cell Division; DNA-Binding Proteins; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Fibroblasts; Immediate-Early Proteins; Immunoblotting; Insulin-Like Growth Factor I; Isoquinolines; Myocardium; Oligopeptides; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred WKY; Receptor, IGF Type 1; Sp1 Transcription Factor; Tetrahydroisoquinolines; Tetrazoles; Time Factors; Transcription Factors	2000

Article

Year

Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts.

Naunyn-Schmiedeberg's archives of pharmacology, 1999, Volume: 359, Issue:5

Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Benzimidazoles; Biphenyl Compounds; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Fibroblasts; Flavonoids; Heart; Immunoblotting; Isoquinolines; Phosphorylation; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Signal Transduction; STAT3 Transcription Factor; Tetrahydroisoquinolines; Tetrazoles; Time Factors; Trans-Activators

1999

Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation.

British journal of pharmacology, 2000, Volume: 131, Issue:8

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Benzimidazoles; Biphenyl Compounds; Bromodeoxyuridine; Cell Division; DNA-Binding Proteins; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Fibroblasts; Immediate-Early Proteins; Immunoblotting; Insulin-Like Growth Factor I; Isoquinolines; Myocardium; Oligopeptides; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred WKY; Receptor, IGF Type 1; Sp1 Transcription Factor; Tetrahydroisoquinolines; Tetrazoles; Time Factors; Transcription Factors

2000